## Ulrik Tarp

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4454510/publications.pdf

Version: 2024-02-01

186265 254184 3,081 42 28 citations h-index papers

g-index 44 44 44 3550 all docs docs citations times ranked citing authors

43

#	Article	IF	CITATIONS
1	Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and Rheumatism, 2010, 62, 22-32.	6.7	459
2	Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry. Arthritis and Rheumatism, 2011, 63, 382-390.	6.7	204
3	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases, 2011, 70, 1575-1580.	0.9	188
4	Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Annals of the Rheumatic Diseases, 2010, 69, 1789-1795.	0.9	168
5	Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis and Rheumatism. 2006. 54. 1401-1409.	6.7	160
6	Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor $\hat{l}_{\pm}$ Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry. Arthritis and Rheumatism, 2013, 65, 1213-1223.	6.7	159
7	Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry. Annals of the Rheumatic Diseases, 2013, 72, 79-82.	0.9	150
8	Teleâ€Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial. Arthritis Care and Research, 2018, 70, 353-360.	3.4	124
9	Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor $\hat{l}\pm$ inhibitor therapy: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases, 2013, 72, 1149-1155.	0.9	123
10	Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases, 2011, 70, 1216-1222.	0.9	112
11	Plasma Adiponectin in Patients with Active, Early, and Chronic Rheumatoid Arthritis Who Are Steroid- and Disease-Modifying Antirheumatic Drug-Naive Compared with Patients with Osteoarthritis and Controls. Journal of Rheumatology, 2009, 36, 1885-1891.	2.0	106
12	The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 515.	6.7	102
13	Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Annals of the Rheumatic Diseases, 2007, 66, 1184-1189.	0.9	90
14	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Annals of the Rheumatic Diseases, 2010, 69, 1596-1602.	0.9	87
15	Delayed Effects of NO <sub>2</sub> Exposure on Alveolar Permeability and Glutathione Peroxidase in Healthy Humans. The American Review of Respiratory Disease, 1992, 146, 654-659.	2.9	74
16	Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Annals of the Rheumatic Diseases, 2012, 71, 851-856.	0.9	70
17	Selenium Treatment in Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 1985, 14, 364-368.	1.1	68
18	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Annals of the Rheumatic Diseases, 2012, 71, 374-377.	0.9	64

#	Article	IF	Citations
19	Low Selenium Level in Severe Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 1985, 14, 97-101.	1.1	61
20	Association between tobacco smoking and response to tumour necrosis factor $\hat{l}_{\pm}$ inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Annals of the Rheumatic Diseases, 2015, 74, 2130-2136.	0.9	54
21	Prenatal Exposure to Methyl Mercury among Greenlandic Polar Inuits. Archives of Environmental Health, 1990, 45, 355-358.	0.4	50
22	Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology, 2017, 56, kew442.	1.9	49
23	Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenetics and Genomics, 2014, 24, 401-405.	1.5	38
24	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Research and Therapy, 2016, 18, 50.	3.5	37
25	Glutathione peroxidase activity in patients with rheumatoid arthritis and in normal subjects: effects of long-term selenium supplementation. Arthritis and Rheumatism, 1987, 30, 1162-1166.	6.7	34
26	Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scandinavian Journal of Rheumatology, 1999, 28, 288-299.	1.1	34
27	High Risk of Ischemic Heart Disease in Patients with Lupus Nephritis. Journal of Rheumatology, 2011, 38, 2400-2405.	2.0	34
28	Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases, 2013, 72, 57-63.	0.9	29
29	A folowup study of children exposed to gold compunds in utero. Arthritis and Rheumatism, 1985, 28, 235-236.	6.7	26
30	Mannose-Binding Lectin Gene Polymorphisms Are Associated with Disease Activity and Physical Disability in Untreated, Anti-Cyclic Citrullinated Peptide-Positive Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 731-735.	2.0	19
31	Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R39.	3.5	19
32	Selenium in rheumatoid arthritis. A review. Analyst, The, 1995, 120, 877.	3.5	18
33	Cartilage Oligomeric Matrix Protein Associates Differentially with Erosions and Synovitis and Has a Different Temporal Course in Cyclic Citrullinated Peptide Antibody (Anti-CCP)-positive versus Anti-CCP-negative Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 1563-1568.	2.0	14
34	Uncoupling of Collagen II Metabolism in Newly Diagnosed, Untreated Rheumatoid Arthritis Is Linked to Inflammation and Antibodies Against Cyclic Citrullinated Peptides. Journal of Rheumatology, 2010, 37, 1113-1120.	2.0	13
35	Which Factors Influence Radiographic Progression During Treatment with Tumor Necrosis Factor Inhibitors in Clinical Practice? Results from 930 Patients with Rheumatoid Arthritis in the Nationwide Danish DANBIO Registry. Journal of Rheumatology, 2014, 41, 2352-2360.	2.0	13
36	Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naA ve rheumatoid arthritis patients is up-regulated and not influenced by 1Âyear of clinically effective treatment. Rheumatology International, 2012, 32, 501-504.	3.0	8

#	Article	IF	CITATIONS
37	Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study. RMD Open, 2020, 6, e001102.	3.8	8
38	Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study. Arthritis Research and Therapy, 2016, 18, 53.	<b>3.</b> 5	5
39	Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study. RMD Open, 2020, 6, e001140.	3.8	4
40	Variant mannose-binding lectin genotypes and outcome in early versus late rheumatoid arthritis: Comment on the article by Ip et al. Arthritis and Rheumatism, 2002, 46, 555-556.	6.7	2
41	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. Annals of the Rheumatic Diseases, 2012, 71, A13.2-A14.	0.9	2
42	Selenium and Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 1986, 15, 96-96.	1.1	1